Walid AbiSaab - Galapagos Executive
| GLPG Stock | USD 25.22 0.42 1.64% |
Executive
Mr. Walid AbiSaab was Member of the Executive Committee, Chief Medical Officer of Galapagos NV since March 2017. He drives the overall medical strategy of the Company and is responsible for late stage clinical development and operations, medical and regulatory affairs, and safety. Before, hebworked at Shire Pharmaceuticals where he held various clinical development leadership roles, most recently as Group Vice President, Global Clinical Development Therapeutic Area Head, Gastrointestinal, Endocrinology and Metabolism. Prior to that, he led clinical development activities at Novartis, Abbott Laboratories and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process. Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada. Prior to his pharma roles, he was Assistant Professor of Psychiatry and Neurosurgery at Yale University Medical School, where he headed their Schizophrenia Research at the Clinical Neuroscience Research Unit and the Neurosurgery Epilepsy Microdialysis Research Program since 2017.
| Age | 59 |
| Tenure | 7 years |
| Address | Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 |
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0238) % which means that it has lost $0.0238 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0221) %, meaning that it created substantial loss on money invested by shareholders. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Galapagos' Return On Equity is most likely to increase slightly in the upcoming years. At this time, Galapagos' Total Current Assets are most likely to increase significantly in the upcoming years. The Galapagos' current Intangible Assets is estimated to increase to about 125.1 M, while Intangibles To Total Assets are projected to decrease to 0.04.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chau MBA | CytomX Therapeutics | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Stacy Rollinger | NextCure | N/A | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Udayan MD | NextCure | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Richard Colonno | Assembly Biosciences | 74 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Kevin Shaw | NextCure | 49 | |
| Sebastien Maloveste | NextCure | N/A | |
Management Performance
| Return On Equity | -0.0221 | ||||
| Return On Asset | -0.0238 |
Galapagos NV ADR Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andre Hoekema, Sr. VP of Corporate Devel. | ||
| John Montana, Managing Argenta | ||
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
| Marieke Vermeersch, Head Communication | ||
| Patrik Ringblom, Head Lead | ||
| Ellen Aar, Head Development | ||
| Dirk Naeyer, Head Operations | ||
| Annelies Missotten, Executive Officer | ||
| Alice Dietrich, Head Affairs | ||
| Philippe Alen, Senior Development | ||
| Thad CMA, CFO VP | ||
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
| Michele MBA, Head Commercial | ||
| Chantal Tasset, Head Devel | ||
| Thad Huston, CFO COO | ||
| Sofie Gijsel, Head Relations | ||
| MBA MBA, COO Pres | ||
| Valeria Cnossen, Executive Counsel | ||
| PharmD Raboisson, Head VP |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0221 | ||||
| Return On Asset | -0.0238 | ||||
| Profit Margin | 0.79 % | ||||
| Operating Margin | (0.91) % | ||||
| Current Valuation | (1.84 B) | ||||
| Shares Outstanding | 65.9 M | ||||
| Shares Owned By Institutions | 32.00 % | ||||
| Number Of Shares Shorted | 1.42 M | ||||
| Price To Earning | (15.60) X | ||||
| Price To Book | 0.55 X |
Currently Active Assets on Macroaxis
When determining whether Galapagos NV ADR is a strong investment it is important to analyze Galapagos' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galapagos' future performance. For an informed investment choice regarding Galapagos Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galapagos. If investors know Galapagos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galapagos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.748 | Earnings Share (0.97) | Revenue Per Share 0.1977 | Quarterly Revenue Growth (0.50) | Return On Assets (0.02) |
The market value of Galapagos NV ADR is measured differently than its book value, which is the value of Galapagos that is recorded on the company's balance sheet. Investors also form their own opinion of Galapagos' value that differs from its market value or its book value, called intrinsic value, which is Galapagos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galapagos' market value can be influenced by many factors that don't directly affect Galapagos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.